All In MedTech

Device Trial Radar · NCT07591051

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Jul 2029

Study completion Jan 2033

Sponsor

Lead sponsor
University of ZurichAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 15, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria. Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints. This study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for regionally metastatic prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality. Weekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population. A diagnostic high field MRI during radiotherapy, e.g. week 3 is optional. Follow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).

Conditions

  • Prostate Cancer

Interventions

  • weekly CT or MR online adaptive definitive SBRTDevice

    Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility- a successful delivery of CT or MR-informed SBRT per fractionTime frame: from Day 1 of treatment up to 7 weeks until end of treatment
  2. Safety - Adverse eventsTime frame: ≥ 3 months to within 1 year after completion of SBRT

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • University Clinic Heidelberg

    Heidelberg, Baden-Würtemberg, Germany

  • University Hospital Zurich

    Zurich, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.